RNA Editing for Neurodegenerative Diseases Market: Key Company Profiles

RNA Editing for Neurodegenerative Diseases Market Companies

• ADARx Pharmaceuticals
• Amber Bio
• Ascidian Therapeutics
• Beam Therapeutics
• Eli Lilly & Co.
• GSK Plc
• Korro Bio
• Moderna Inc.
• ProQR Therapeutics
• Roche Holding AG
• Shape Therapeutics
• Takeda Pharmaceutical Company
• Verve Therapeutics
• Wave Life Sciences
• Regeneron Pharmaceuticals

Download Sample Report

ADARx Pharmaceuticals

• Company Name and Headquarters: ADARx Pharmaceuticals, Inc. – San Diego, California, USA

• Product Offerings related to RNA Editing for Neurodegenerative Diseases: ADARx is focused on developing RNA editing therapeutics utilizing its proprietary ADARx platform. While their broader pipeline includes programs for various genetic diseases, their neurodegenerative disease focus is emerging, leveraging ADAR editing to correct disease-causing mutations or modulate protein expression. Specific product candidates for neurodegenerative diseases are in preclinical stages.

• Market Share and Estimated Revenue from RNA Editing for Neurodegenerative Diseases Segment: As a relatively newer player with programs primarily in preclinical development, ADARx currently holds negligible market share in commercial RNA editing for neurodegenerative diseases. Revenue from this specific segment is not yet estimable as no products are marketed.

• Recent Developments, Partnerships, or Innovations:

  • Significant venture capital funding rounds to advance its pipeline.

  • Ongoing preclinical research demonstrating the potential of its ADAR platform in various disease models.

  • Focus on optimizing oligonucleotide delivery for tissue-specific RNA editing.

• Competitive Positioning and Strategic Focus: ADARx positions itself as an innovator in ADAR-mediated RNA editing, aiming for highly specific and reversible genetic modifications. Their strategic focus is on building a robust preclinical pipeline and advancing lead candidates into clinical trials, potentially through partnerships with larger pharmaceutical companies for late-stage development and commercialization.

• Key Customers or Industries Served: Primarily research institutions and, in the future, patients suffering from neurodegenerative and other genetic diseases.

Amber Bio

• Company Name and Headquarters: Amber Bio – South San Francisco, California, USA

• Product Offerings related to RNA Editing for Neurodegenerative Diseases: Amber Bio is a biotechnology company focused on developing RNA editing therapeutics, particularly leveraging ADAR enzymes. Their programs are aimed at correcting mutations or altering protein expression for various genetic diseases, including those impacting the nervous system. Specific preclinical programs for neurodegenerative diseases are in development.

• Market Share and Estimated Revenue from RNA Editing for Neurodegenerative Diseases Segment: Amber Bio is a privately held, early-stage company. It holds no current market share, and revenue from this segment is not applicable as products are in preclinical development.

• Recent Developments, Partnerships, or Innovations:

  • Emergence from stealth mode with significant seed funding.

  • Focus on developing novel computational and experimental platforms to identify optimal ADAR editing sites and guide oligonucleotide design.

  • Emphasizing high-fidelity and target-specific RNA editing.

• Competitive Positioning and Strategic Focus: Amber Bio aims to differentiate itself through its advanced computational approaches and its ability to precisely target and execute RNA editing. Their strategic focus is on rapid discovery and optimization of RNA editing candidates, with an eye towards efficient translation into clinical development, potentially seeking partnerships for broader application.

• Key Customers or Industries Served: Research collaborators and, ultimately, patients with genetic diseases.

Ascidian Therapeutics

• Company Name and Headquarters: Ascidian Therapeutics – Boston, Massachusetts, USA

• Product Offerings related to RNA Editing for Neurodegenerative Diseases: Ascidian Therapeutics is developing RNA exon editing therapeutics that enable single oligonucleotides to modify multiple exons, thereby producing full-length, functional proteins. This approach has broad potential for neurodegenerative diseases where truncated or misfolded proteins are implicated. Specific programs are in early-stage development.

• Market Share and Estimated Revenue from RNA Editing for Neurodegenerative Diseases Segment: As an early-stage company with programs in preclinical development, Ascidian Therapeutics holds no current market share, and revenue from this segment is not applicable.

• Recent Developments, Partnerships, or Innovations:

  • Significant Series A financing round.

  • Focus on its “exon editing” platform, which represents a novel approach distinct from single-nucleotide RNA editing.

  • Preclinical data showing the potential to restore full-length protein function.

• Competitive Positioning and Strategic Focus: Ascidian’s exon editing platform offers a unique competitive advantage by potentially addressing larger genetic defects than single-nucleotide editing. Their strategic focus is on validating this platform across multiple disease areas, including neurodegenerative diseases, and advancing lead candidates into IND-enabling studies. They aim to be a leader in exon-level RNA modulation.

• Key Customers or Industries Served: Research institutions and, eventually, patients with severe genetic disorders.

Beam Therapeutics

• Company Name and Headquarters: Beam Therapeutics Inc. – Cambridge, Massachusetts, USA

• Product Offerings related to RNA Editing for Neurodegenerative Diseases: Beam Therapeutics is a leader in base editing, a precise gene editing technology that makes single-base changes in DNA (not strictly RNA editing, but highly relevant for genetic diseases). However, their technology has implications for RNA regulation, and their broader expertise in genetic medicine positions them to potentially develop RNA-modulating therapies or target genes associated with neurodegeneration. They have programs in neurology, but specific RNA editing candidates for neurodegenerative diseases are less prominent than their DNA base editing focus.

• Market Share and Estimated Revenue from RNA Editing for Neurodegenerative Diseases Segment: Beam’s current market share and revenue are primarily derived from its DNA base editing programs. Revenue directly from RNA editing for neurodegenerative diseases is negligible, as their core focus is DNA.

• Recent Developments, Partnerships, or Innovations:

  • Advancement of multiple in vivo base editing programs towards clinical trials.

  • Partnerships with various pharmaceutical companies for specific programs.

  • Continuous innovation in improving the efficiency and safety of base editing technologies.

• Competitive Positioning and Strategic Focus: Beam is a pioneer in base editing, offering a precise alternative to traditional CRISPR. While their core is DNA editing, their strategic focus on in vivo delivery and genetic disease correction positions them as a key player in the broader genetic medicines space, with potential to indirectly impact or pivot towards RNA editing strategies for neurodegeneration in the future. Their competitive edge is the precision of base editing.

• Key Customers or Industries Served: Patients with genetic diseases, pharmaceutical partners, and research institutions.

Eli Lilly & Co.

• Company Name and Headquarters: Eli Lilly and Company – Indianapolis, Indiana, USA

• Product Offerings related to RNA Editing for Neurodegenerative Diseases: As a large pharmaceutical company, Lilly is a significant investor in neurodegenerative disease research. Their involvement in RNA editing for neurodegenerative diseases typically comes through partnerships, acquisitions, or internal discovery efforts, often focusing on oligonucleotide therapeutics (ASOs, siRNAs) that can modulate RNA rather than direct editing. They are exploring various modalities, including those that could leverage RNA editing technologies.

• Market Share and Estimated Revenue from RNA Editing for Neurodegenerative Diseases Segment: Lilly’s market share in RNA editing for neurodegenerative diseases is currently minimal, as most of their major neurodegenerative products are not based on this specific modality. Revenue contribution from direct RNA editing products is not yet significant.

• Recent Developments, Partnerships, or Innovations:

  • Investments in neuroscience research, including genetic and RNA-based therapies.

  • Partnerships with smaller biotech companies developing novel therapeutic platforms, some of which may include RNA editing.

  • Ongoing clinical trials for various neurodegenerative diseases with diverse mechanisms of action.

• Competitive Positioning and Strategic Focus: Lilly’s strategic focus in neurodegenerative diseases is broad, aiming to address significant unmet needs. They leverage their vast R&D resources and global commercialization capabilities. In the RNA editing space, their strategy is likely opportunistic, seeking best-in-class technologies through partnerships or acquisitions to complement their existing neuroscience pipeline.

• Key Customers or Industries Served: Patients with neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s), clinicians, and healthcare systems globally.

GSK Plc

• Company Name and Headquarters: GSK Plc – London, United Kingdom

• Product Offerings related to RNA Editing for Neurodegenerative Diseases: GSK, a global pharmaceutical giant, has a strong interest in genetic medicines and neuroscience. Their approach to RNA editing for neurodegenerative diseases is typically through strategic partnerships, investments in platform technologies, or internal research into novel RNA-targeting modalities. While not having a dedicated “RNA editing” platform themselves in the same way as specialized biotechs, they are actively exploring and investing in technologies that can modify RNA to treat disease.

• Market Share and Estimated Revenue from RNA Editing for Neurodegenerative Diseases Segment: GSK’s market share and revenue from specific RNA editing products for neurodegenerative diseases are currently negligible as their primary commercial offerings in neurology are not based on this technology.

• Recent Developments, Partnerships, or Innovations:

  • Strategic focus on genetic medicines, including functional genomics and advanced therapeutic modalities.

  • Collaborations with biotech companies specializing in gene and RNA technologies.

  • Investment in AI and machine learning for drug discovery, which can identify potential RNA targets.

• Competitive Positioning and Strategic Focus: GSK’s strategy is to build a robust pipeline in areas of high unmet medical need, including neurodegeneration, by leveraging external innovation and its internal R&D strengths. In RNA editing, they are likely to partner with or acquire companies that have validated platforms, rather than developing a de novo platform themselves. Their competitive strength lies in their broad R&D capabilities and global reach.

• Key Customers or Industries Served: Patients, healthcare providers, and health systems globally.

Korro Bio

• Company Name and Headquarters: Korro Bio, Inc. – Cambridge, Massachusetts, USA

• Product Offerings related to RNA Editing for Neurodegenerative Diseases: Korro Bio is a leading company in RNA editing, specifically utilizing ADAR (adenosine deaminase acting on RNA) enzymes to make targeted, programmable edits to RNA. They have developed an ” engineered RNA editor ” (ARES™ platform) designed for high precision. Their pipeline includes programs for various diseases, with a significant focus on neurological disorders, including neurodegenerative diseases, by correcting pathogenic mutations or upregulating protective proteins.

• Market Share and Estimated Revenue from RNA Editing for Neurodegenerative Diseases Segment: Korro Bio is a clinical-stage company. While they have strong preclinical data and advancing programs, they do not yet have commercialized products, so their current market share and revenue from the RNA editing for neurodegenerative diseases segment are negligible.

• Recent Developments, Partnerships, or Innovations:

  • Advancement of lead programs towards IND-enabling studies and clinical trials.

  • Strong preclinical data showing durable and specific RNA editing in vivo.

  • Significant funding rounds to support pipeline development.

  • Focus on optimizing oligonucleotide chemistry and delivery for CNS applications.

• Competitive Positioning and Strategic Focus: Korro Bio is a pure-play RNA editing company, positioning itself as a leader in ADAR-mediated therapeutic RNA editing. Their strategic focus is on rapidly translating their ARES™ platform into clinical candidates for diseases with high unmet needs, particularly in neurology. They aim to be a first-in-class or best-in-class developer of RNA editing therapies, potentially seeking partnerships for broader commercialization.

• Key Customers or Industries Served: Research institutions and, ultimately, patients with genetic and neurodegenerative diseases.

Moderna Inc.

• Company Name and Headquarters: Moderna, Inc. – Cambridge, Massachusetts, USA

• Product Offerings related to RNA Editing for Neurodegenerative Diseases: Moderna is a pioneer in mRNA therapeutics. While their primary focus has been on mRNA vaccines and protein replacement therapies, their core expertise in mRNA biology, delivery (LNP technology), and manufacturing provides a strong foundation for exploring RNA editing applications. They are actively involved in developing various mRNA-based therapeutics, and their research could extend to strategies that induce or leverage endogenous RNA editing mechanisms, or deliver RNA editing machinery. Their neurodegenerative disease pipeline is primarily focused on delivering therapeutic proteins or vaccines, but their broader RNA capabilities are relevant.

• Market Share and Estimated Revenue from RNA Editing for Neurodegenerative Diseases Segment: Moderna’s market share and revenue are overwhelmingly dominated by its mRNA vaccine products. While they have extensive RNA expertise, direct revenue from RNA editing products for neurodegenerative diseases is negligible as it’s not their primary commercial focus in this area yet.

• Recent Developments, Partnerships, or Innovations:

  • Massive scale-up of mRNA manufacturing capabilities.

  • Expansion of their therapeutic pipeline beyond infectious diseases, including rare genetic diseases and oncology.

  • Ongoing research into next-generation mRNA delivery systems and targeting.

  • Partnerships to explore novel mRNA applications.

• Competitive Positioning and Strategic Focus: Moderna is a global leader in mRNA technology. Their strategic focus is on leveraging their mRNA platform for a wide range of therapeutic applications. While not a pure-play RNA editing company, their deep understanding of RNA biology and delivery positions them as a potential major player if they choose to fully enter the RNA editing space, possibly through collaborations or acquisitions.

• Key Customers or Industries Served: Patients globally, governments, and healthcare systems.

ProQR Therapeutics

• Company Name and Headquarters: ProQR Therapeutics N.V. – Leiden, Netherlands

• Product Offerings related to RNA Editing for Neurodegenerative Diseases: ProQR is a biotechnology company focused on RNA therapies, primarily using oligonucleotides to correct or modulate RNA. They have developed various RNA-targeting platforms, including those that aim to correct mutations at the RNA level. While their lead programs have historically been in ophthalmic diseases, their expertise in RNA repair and modulation is highly transferable to neurodegenerative diseases. They have explored applications in neurological disorders, often through read-through or splice modification strategies that indirectly affect RNA.

• Market Share and Estimated Revenue from RNA Editing for Neurodegenerative Diseases Segment: ProQR is a clinical-stage company. Its market share and revenue from direct RNA editing for neurodegenerative diseases are negligible, as commercial products are not yet available in this specific area.

• Recent Developments, Partnerships, or Innovations:

  • Clinical development of RNA-based therapies for genetic diseases.

  • Focus on optimizing oligonucleotide chemistry for improved efficacy and delivery.

  • Partnerships to expand the application of their RNA platform.

  • Exploration of novel RNA repair mechanisms.

• Competitive Positioning and Strategic Focus: ProQR positions itself as an innovator in RNA-based medicines, leveraging its proprietary oligonucleotide platforms. Their strategic focus is on developing disease-modifying RNA therapies for severe genetic disorders. While not strictly an “RNA editing” company in the ADAR-enzyme sense, their technologies achieve similar therapeutic outcomes by modulating RNA at specific sites, making them a relevant player in the broader RNA repair/modulation landscape for neurodegenerative diseases.

• Key Customers or Industries Served: Patients with genetic diseases, research institutions.

Roche Holding AG

• Company Name and Headquarters: Roche Holding AG – Basel, Switzerland

• Product Offerings related to RNA Editing for Neurodegenerative Diseases: Roche is a global pharmaceutical and diagnostics giant with a substantial presence in neuroscience. Their involvement in RNA editing for neurodegenerative diseases is primarily through strategic partnerships, investments in cutting-edge biotechnologies, and internal research. They are actively engaged in oligonucleotide therapeutics (e.g., ASOs for SMA with Spinraza) and are exploring various gene and RNA-modulating therapies for neurodegenerative conditions like Alzheimer’s, Parkinson’s, and Huntington’s disease. They will likely partner with or acquire companies specializing in RNA editing platforms.

• Market Share and Estimated Revenue from RNA Editing for Neurodegenerative Diseases Segment: Roche has a significant market presence in neurodegenerative diseases with existing therapies. However, their market share and revenue specifically from RNA editing products in this segment are currently negligible, as most of their commercial offerings do not use this precise technology.

• Recent Developments, Partnerships, or Innovations:

  • Extensive R&D in neuroscience, including gene therapy and oligonucleotide modalities.

  • Numerous collaborations with biotech companies working on novel genetic medicine platforms.

  • Clinical programs for a range of neurodegenerative diseases.

• Competitive Positioning and Strategic Focus: Roche’s strategic focus is on being a leader in personalized healthcare, which includes developing highly targeted therapies for complex diseases like neurodegeneration. They leverage their vast R&D capabilities, global commercial infrastructure, and diagnostic expertise. In the RNA editing space, their strategy is to identify and integrate promising external technologies to enhance their pipeline and address unmet patient needs.

• Key Customers or Industries Served: Patients, healthcare professionals, hospitals, and diagnostic labs globally.

Shape Therapeutics

• Company Name and Headquarters: Shape Therapeutics, Inc. – Seattle, Washington, USA

• Product Offerings related to RNA Editing for Neurodegenerative Diseases: Shape Therapeutics is a pioneering company in RNA editing, utilizing their proprietary “ShapeR” platform which leverages engineered ADAR enzymes and a “forMA” (forgetting RNA guide sequences using machine learning) computational platform. They aim to correct genetic mutations at the RNA level or modulate protein expression, with a strong focus on neurological disorders. Their pipeline includes programs for various neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and other rare genetic disorders.

• Market Share and Estimated Revenue from RNA Editing for Neurodegenerative Diseases Segment: Shape Therapeutics is a preclinical- and early clinical-stage company. It holds no current market share, and revenue from this segment is not applicable as products are not yet commercialized.

• Recent Developments, Partnerships, or Innovations:

  • Strategic partnerships with major pharmaceutical companies (e.g., Roche).

  • Significant funding rounds to advance its RNA editing platforms and pipeline.

  • Strong preclinical data demonstrating precise and durable RNA editing in vivo.

  • Development of advanced AAV-based delivery systems for CNS targeting.

• Competitive Positioning and Strategic Focus: Shape Therapeutics is a frontrunner in the therapeutic RNA editing space, particularly with its engineered ADAR platform and sophisticated computational tools. Their strategic focus is on developing a robust pipeline of in vivo RNA editing therapies for neurodegenerative and other genetic diseases, leveraging their partnerships for broad development and potential commercialization. They aim to be a leader in the next generation of genetic medicines.

• Key Customers or Industries Served: Research institutions and, eventually, patients with severe genetic and neurodegenerative diseases.

Takeda Pharmaceutical Company

• Company Name and Headquarters: Takeda Pharmaceutical Company Limited – Tokyo, Japan (Global HQ)

• Product Offerings related to RNA Editing for Neurodegenerative Diseases: Takeda is a large, global pharmaceutical company with a significant focus on neuroscience and rare diseases. Their involvement in RNA editing for neurodegenerative diseases typically comes through strategic partnerships, investments, or internal research into advanced therapeutic modalities. While not having a dedicated “RNA editing” platform themselves, they actively collaborate on and explore gene- and RNA-based therapies, including those that modify RNA expression or function, to address neurodegenerative conditions.

• Market Share and Estimated Revenue from RNA Editing for Neurodegenerative Diseases Segment: Takeda’s market share and revenue in the neurodegenerative space are derived from existing products in their portfolio. Direct revenue from RNA editing products for neurodegenerative diseases is currently negligible as no commercial products are based solely on this technology.

• Recent Developments, Partnerships, or Innovations:

  • Significant investments in neuroscience R&D, including advanced cellular and genetic therapies.

  • Partnerships with biotech companies developing novel therapeutic platforms.

  • Focus on rare neurodevelopmental and neurodegenerative disorders.

• Competitive Positioning and Strategic Focus: Takeda’s strategic focus in neuroscience is on developing innovative treatments for debilitating neurological and rare genetic diseases. They leverage their global R&D network and commercial presence. In the RNA editing space, their strategy is likely to identify and collaborate with or acquire companies that have validated platforms, integrating these technologies into their broader pipeline to address high unmet medical needs.

• Key Customers or Industries Served: Patients, healthcare providers, and health systems globally.

Verve Therapeutics

• Company Name and Headquarters: Verve Therapeutics, Inc. – Cambridge, Massachusetts, USA

• Product Offerings related to RNA Editing for Neurodegenerative Diseases: Verve Therapeutics is a clinical-stage company focused on in vivo gene editing (primarily base editing of DNA) to permanently lower disease-causing genes for cardiovascular disease. While their primary focus is cardiovascular, their expertise in in vivo delivery of gene editing tools, particularly base editors, is highly relevant to the broader field of genetic medicines. If they were to expand into neurodegenerative diseases, they would likely adapt their DNA base editing technology or potentially integrate RNA editing strategies given their deep understanding of nucleic acid therapeutics and delivery. Currently, they do not have specific RNA editing programs for neurodegenerative diseases.

• Market Share and Estimated Revenue from RNA Editing for Neurodegenerative Diseases Segment: Verve is a clinical-stage company with no commercial products. Its market share and revenue from RNA editing for neurodegenerative diseases are negligible.

• Recent Developments, Partnerships, or Innovations:

  • Advancement of their lead base editing candidates for cardiovascular disease into clinical trials.

  • Development of novel lipid nanoparticle (LNP) delivery systems.

  • Strategic collaborations with other gene editing companies.

• Competitive Positioning and Strategic Focus: Verve is a pioneer in using gene editing to address cardiovascular disease by modifying genes in the liver. Their strategic focus is to prove the long-term efficacy and safety of in vivo gene editing for common diseases. While not directly an RNA editing company for neurodegeneration, their success in gene editing delivery and application could pave the way for future expansion into neurodegenerative RNA editing, either through internal programs or partnerships.

• Key Customers or Industries Served: Patients with cardiovascular diseases, research institutions.

Wave Life Sciences

• Company Name and Headquarters: Wave Life Sciences Ltd. – Cambridge, Massachusetts, USA (and Osaka, Japan)

• Product Offerings related to RNA Editing for Neurodegenerative Diseases: Wave Life Sciences is a clinical-stage genetic medicines company focused on developing stereopure oligonucleotide therapeutics. Their platform, PRISM™, enables the design of highly specific and potent oligonucleotides, including antisense oligonucleotides (ASOs) and exon-skipping drugs. While their lead programs are in Huntington’s disease, ALS, and other neurological conditions, their approach is primarily focused on modulating RNA expression, splicing, or degradation, rather than direct “editing” in the sense of changing a single nucleotide via an enzyme. However, their RNA-targeting expertise is highly relevant to achieving similar therapeutic outcomes for neurodegenerative diseases.

• Market Share and Estimated Revenue from RNA Editing for Neurodegenerative Diseases Segment: Wave Life Sciences is a clinical-stage company with no commercial products, so its market share and revenue from RNA editing-like products for neurodegenerative diseases are negligible.

• Recent Developments, Partnerships, or Innovations:

  • Advancement of clinical programs for Huntington’s disease and ALS.

  • Optimization of stereopure oligonucleotide chemistry for enhanced potency, durability, and safety.

  • Development of novel delivery approaches for CNS targeting.

  • Strategic collaborations with major pharmaceutical companies.

• Competitive Positioning and Strategic Focus: Wave Life Sciences differentiates itself through its proprietary stereopure oligonucleotide chemistry, which aims to improve the therapeutic index of RNA-modulating drugs. Their strategic focus is on addressing severe genetic diseases with high unmet needs, particularly in neurology. While not strictly an “RNA editing” company, their ability to precisely modulate RNA function makes them a significant player in the broader RNA-based therapeutics landscape for neurodegenerative diseases.

• Key Customers or Industries Served: Patients with genetic neurological disorders, research institutions, pharmaceutical partners.

Regeneron Pharmaceuticals

• Company Name and Headquarters: Regeneron Pharmaceuticals, Inc. – Tarrytown, New York, USA

• Product Offerings related to RNA Editing for Neurodegenerative Diseases: Regeneron is a leading biotechnology company known for its proprietary VelocImmune mouse technology and its focus on developing antibody and protein therapeutics. While their primary modalities are not inherently RNA editing, Regeneron has a strong commitment to genetic medicines and neuroscience. Their investment in cutting-edge technologies, including gene silencing (e.g., with Alnylam Pharmaceuticals for RNAi therapies) and gene therapy, positions them to explore or integrate RNA editing approaches for neurodegenerative diseases, likely through partnerships or internal discovery efforts.

• Market Share and Estimated Revenue from RNA Editing for Neurodegenerative Diseases Segment: Regeneron has a strong market presence in several therapeutic areas. However, their market share and direct revenue from RNA editing products for neurodegenerative diseases are currently negligible as this is not a core commercialized modality for them.

• Recent Developments, Partnerships, or Innovations:

  • Extensive R&D in human genetics and complex diseases.

  • Strategic collaborations, including those in RNA interference (RNAi) and gene therapy.

  • Active pipeline in neurological disorders, often leveraging their antibody and gene therapy platforms.

• Competitive Positioning and Strategic Focus: Regeneron’s strategic focus is on discovering and developing innovative medicines based on a deep understanding of human genetics. They leverage their unique technologies (like VelocImmune and VelociGene) to identify and validate targets. In the RNA editing space, their strategy would likely be to partner with or acquire companies that possess validated platforms to complement their existing neuroscience pipeline, focusing on targets identified through their genetic research.

• Key Customers or Industries Served: Patients, healthcare providers, and health systems globally.

Contact Us